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Abstract: Background: Migraine is a primary headache disorder. Despite numerous studies 
conducted with the aim to understand the pathophysiology of migraine, several aspects are 
still unclear. The trigeminovascular system plays a key role. Neurogenic inflammation is pre-
sumed to be an important factor in migraine pathophysiology, mediated by the activation of 
primary neurons, leading to the release of various pro-inflammatory neuropeptides and neuro-
transmitters such as Calcitonin Gene-Related Peptide (CGRP), substance P (SP), and vasoac-
tive intestinal peptide (VIP). Nitric oxide (NO), Pituitary adenylate cyclase-activating poly-
peptide (PACAP) and Glutamate (Glu) also play an important role in the modulation of in-
flammatory mechanisms. 
Objective: To review the literature focusing on novel therapeutic targets in migraine, related 
to neurogenic inflammation. 
Method: A systematic literature search in the database of PUBMED was conducted regarding 
therapeutic strategies in migraine, focusing on substances and cytokines released during neu-
rogenic inflammation, published in January 2017. 
Results: Ongoing phase III clinical studies with monoclonal antibodies against CGRP and 
CGRP receptors offer promising novel aspects for migraine treatment. Preclinical and clinical 
studies targeting SP and nitric oxide synthase (NOS) were all terminated with no significant 
result compared to placebo. New promising therapeutic goal could be PACAP and its receptor 
(PAC1), and kynurenic acid (KYNA) analogues. 
Conclusion: Current migraine treatment offers pain relief only for a small proportion of mi-
graine patients and might not be adequate for patients with cardiovascular comorbidity due to 
side effects. Better understanding of migraine pathophysiology might, therefore, lead to novel 
therapeutic lines both in migraine attack treatment and prophylaxis. 
Keywords: Neurogenic inflammation, trigeminovascular system, Calcitonin-gene related peptide, Pituitary adeny-
late cyclase activating polypeptide, kynurenic acid, migraine. 
1. INTRODUCTION 
1.1. Migraine 
Migraine is a painful episodic neurological disease 
being the third most prevalent and the seventh most 
disabling disease worldwide [1]. Migraine has not only 
a large impact on individual and public health but its 
socio-economic costs are extensive [2, 3]. Clinically, 
migraine pain is considered a unilateral, pulsating 
headache, aggravated by coughing or physical activity 
______________________________________________________ 
*Address correspondence to this author at the Department of Neurology, University of Szeged, Hungary and MTA-SZTE Neuroscience Re-
search Group, Szeged, Hungary; Tel: +3662545384; Fax: +3662545597; E-mail: laszlo.vecsei@med.u-szeged.hu 
2    Current Medicinal Chemistry, 2017, Vol. 24, No. 00 Lukács et al. 
associated with nausea, vomiting, and photophobia [4]. 
The attack can be preceded by the aura phenomenon 
that occurs in the wake of the migraine attack and is 
represented in 99% of cases by visual symptoms (sco-
tomas, flashing lights etc.). Nonvisual aura presents 
mainly as sensory symptoms (paresthesia); however, 
but rare auras like olfactory hallucinations, language 
difficulties (dysarthria) or temporary muscle weakness 
(hemiparesis in case of familial hemiplegic migraine- 
FHM) might also occur [4-6]. According to the latest 
classification of the International Headache Society 
migraine can be divided into episodic (migraine with or 
without aura) and chronic form (headache occurs on at 
least 15 days per month with more than 8 typical mi-
graine attacks lasting for at least 3 months) [6].Various 
studies have addressed the pathophysiology of mi-
graine but some aspects still remain unclear. Neverthe-
less, we can firmly postulate that the trigeminovascular 
system plays a crucial role in the generation and trans-
mission of pain sensation. The system consists of the 
trigeminal ganglion (TG) with pseudounipolar neurons 
that innervate the meningeal vasculature and project 
centrally to the second-order neurons of the trigeminal 
nucleus caudalis (TNC) in the brainstem extending to 
the C1-C2 region of the spinal cord [7]. These second-
order neurons transmit pain signals into the thalamus 
and cortical regions [8, 9]. Recent neuroimaging stud-
ies revealed other regions of the central nervous system 
(CNS) (ex. cerebellum, insula, pulvinar, etc.) that 
might play a role in the modulation of pain sensation 
[10, 11]. In 1938, Wolff and coworkers have set up the 
vascular theory of migraine headache, suggesting that 
the headache might be generated in the cranial arteries 
due to a short vasoconstriction and a reactive vasodila-
tion occurring during a migraine attack [12]. New find-
ings have questioned this theory. Currently the concept 
is that migraine is a neurovascular disorder, that origi-
nates in the CNS causing a hypersensitivity of the pe-
ripheral trigeminal nerve fibers that innervate menin-
geal blood vessels [13]. 
Regarding migraine treatment different medications 
are used for an acute migraine attack and for preven-
tion. For acute migraine treatment non-steroid anti-
inflammatory drugs (NSAID) like aspirin, ibuprofen, 
diclofenac or naproxen are recommended. However, 
these are not migraine specific and pain restarts after 2-
4 hours in almost 80% of patients [14-17]. Triptans are 
small agonist molecules acting on 5-HT1B/1D receptors 
and represent level A recommendation according to the 
European Federation of Neurological Societies (EFNS) 
guideline [18, 19]. Certain aspects of their mechanism 
of action in migraine pain relief is, however, still un-
clear [20]. One possible site of action could be an in-
hibitory effect on plasma protein extravasation and 
neurogenic inflammation [21]. Clinical trials show 
pain-relief in 28-59% of the cases [22], the proportion 
of pain-free patients after 2 hours following oral treat-
ment is 18-58% [23]. After application of sumatriptan 
severe cardio- and cerebrovascular adverse events have 
been reported [24], therefore triptans are contraindi-
cated in hypertension, Raynaud syndrome, coronary 
artery disease, stroke and in pregnancy [19]. Their use 
is restricted to 9 days per month as high risk for chroni-
fication was noted following the use of 12 days per 
month [25, 26]. Therefore, treating chronic migraine 
represents a therapeutic challenge for both clinicians 
and researchers. Preventive daily treatment is needed 
when headache frequency exceeds 8-10 days per month 
or the use of NSAIDs or triptans for more than 8-9 
days per month is needed [27]. Beta-blockers (me-
toprolol, propranolol), calcium channel blockers (flu-
narizine), antiepileptic drugs (valproic acid, topi-
ramate) or antidepressants (amitriptyline, venlafaxine) 
are recommended for migraine prevention [19]. Lately 
Botulinum toxin A (BoNTA) has proven to be effective 
and it improves the quality of life in chronic migraine 
treatment [28-31]. An important disadvantage of 
BoNTA is its route of administration: intramuscular 
injection in the muscles of the face and neck [28, 30]. 
On the basis of all these, we can conclude that migraine 
is a highly prevalent painful neurological condition 
with an important socio-economic impact. In order to 
reach an optimal disease-control new therapeutic 
strategies are needed, especially in chronic migraine. 
1.2. Neurogenic Inflammation 
The concept of ‘neurogenic inflammation’ was in-
troduced by the classic experiment of Goltz (1874) and 
Bayliss (1901) observing skin vasodilation following 
electrical stimulation of the dorsal horn, that could not 
be linked to the immune system [32]. Activation of 
sensory nerve fibers causes transmission of pain signals 
not only orthodromically, but also antidromically in the 
yet inactive afferent nerve fibers [32, 33]. At the pe-
ripheral ending of the fibers substance P (SP), calci-
tonin gene-related peptide (CGRP), and neurokinin A 
(NKA) are released which lead to the activation of 
various cell-types (endothelial cells, mast cells, macro-
phages, T cells, dendritic cells). Moreover, these cells 
release numerous other substances, such as prosta-
glandins, tumor necrosis factor alpha (TNFα, interleu-
kins (ILs), glutamate (Glu), nerve-growth factor, 
vasoactive intestinal peptide (VIP) also causing plasma 
protein extravasation (Fig. 1), thus creating a whole
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Fig. (1). Neurogenic inflammation. Enhanced activation of the peripheral nerve endings results in the release of various neu-
ropeptides (e.g., CGRP, NPY, SP, and Glu etc.), leading to neurogenic inflammation. This involves, but it is not limited to the 
activation of astrocytes, microglia, and mast cells, which under inflammatory conditions are able to pass the blood-brain barrier 
(BBB). Plasma protein extravasation and BBB dysfunction are also important consequences of neurogenic inflammation. Re-
lease of numerous pro- and anti-inflammatory agents from the cells involved are able to further modify the inflammatory proc-
ess. Higher-order centers of the CNS can intensify the process, leading to a self-amplifying reaction that might cause peripheral 
and central sensitization.  
CGRP = calcitonin gene-related peptide; CNS = central nervous system; DA = dopamine; GABA = gamma-aminobutyric acid; 
Glu = glutamate; 5-HT = serotonin; His = histamine; NPY= neuropeptide Y; PACAP-38 = 38-amino-acid isoform of pituitary 
adenylate cyclase-activating polypeptide, PG = prostaglandins; NO = nitric oxide, NA = noradrenaline (a.k.a. norepinephrine); 
SP = substance P. 
picture of an ’inflammatory state’ [33, 34]. Neurogenic 
inflammation is presumed to be an important factor in 
various neurological diseases: brain injury [35] , neu-
ropathic pain [36], epilepsy [37, 38] and primary head-
ache diseases [39]. A role of neurogenic inflammation 
in migraine pain has been suggested for decades [40]. 
Plasma protein extravasation, an important phenome-
non that occurs in neurogenic and non-neurogenic in-
flammation has been described in animal models of 
trigeminovascular activation: following electrical 
stimulation of the rat TG or chemical stimulation with 
intravenous capsaicin, plasma protein leakage was re-
ported in the dura mater but also within extracranial 
tissues (eyelids, conjunctiva, lips, gingiva) [41]. In 
these models plasma protein extravasation is presumed 
to take place through the fenestrated endothelium of the 
small vessels in the dura mater and is mediated via 
perivascular myelinated and unmyelinated fibers [41, 
42]. Dural neurogenic inflammation is further mediated 
by the release of vasoactive neuropeptides (CGRP, SP, 
and NKA) from the perivascular nerve fibers [43]. 
Plasma protein extravasation has been shown to be 
blocked by triptans and NSAIDs, selectively in the 
dura mater but not in the extracranial structures or in 
the brain or brain vasculature [42, 44, 45]. The process 
of neurogenic inflammation can be self-amplifying, 
where Glu, the major excitatory neurotransmitter, plays 
a key role in sensitization of sensory nerve fibers. Fur-
thermore, CNS centers might aggravate peripheral neu-
rogenic inflammation, playing a crucial role in long-
term potentiating processes which lead to the chronifi-
cation of migraine pain [33]. The above listed proc-
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esses and cytokine mechanisms might have relevance 
not only by offering a better understanding of migraine 
pathophysiology, but might also serve as site of action 
for novel therapeutic approaches. The importance of 
neurogenic inflammation is suggested by the presump-
tion that triptans, the current gold-standard therapy in 
migraine act against neurogenic inflammation as they 
reduce plasma protein extravasation and the release of 
vasoactive peptides (CGRP, substance P) [46, 47]. 
2. THERAPEUTIC TARGETS INVOLVING 
NEUROGENIC INFLAMMATION 
In the present paper, we aimed to review the thera-
peutic possibilities in migraine in relation to neuro-
genic inflammation. A systemic literature search was 
conducted in the database of PUBMED in January 
2017. The search strings used were: “migraine”, “neu-
rogenic inflammation”, and “migraine treatment”. 
2.1. Calcitonin Gene-related Peptide (CGRP) 
CGRP is a 37-amino-acid protein shown to be 
linked to migraine pathophysiology and neurogenic 
inflammation [48]. It has a vasodilatory effect and 
plays a role in the transmission of pain sensation [49]. 
CGRP exists in two active forms differing only in three 
amino acids in humans: α-CGRP is expressed in the 
peripheral and central nervous system, whereas β-
CGRP is expressed predominantly in the enteric nerv-
ous system [50, 51]. The structure of human α-CGRP 
contains four domains: the first seven residues with the 
N-terminal, linked together by a disulfide bridge form 
the first domain. The second domain is built up by 
residues 8-18, deletion of this domain causes high de-
crease in binding affinity. The third domain contains 
residues 19-27 and whereas the fourth domain is made 
up by residues 28-37containing the C-terminus repre-
senting the binding epitope [52]. The structure of hu-
man CGRP is presented in Fig. (2). 
In the 90’s, calcitonin receptor-like receptor (CLR) 
was discovered, consisting of 461 amino acids with 
seven transmembrane domains [53, 54]. As CLR is 
widely expressed in different cell types, another protein 
called receptor activity modifying protein (RAMP) is 
needed for the site-specific bioactivity of CGRP. Three 
types of RAMPS are known: RAMP1, RAMP2 and 
RAMP3. These receptors become activated by the het-
erodimerization of one transmembrane RAMP and 
CLR proteins [55]. Heterodimerization of CLR and 
RAMP1 creates a CGRP receptor with high binding 
affinity for CGRP (Fig. 3), while co-expression of CLR 
and RAMP2 or RAMP3 yields adrenomedullin recep-
tors (AM1 and AM2 receptor) [56]. The mechanism of 
CGRP binding to the receptor is referred to as the ’two-
domain model’. During the first step, the COOH termi-
nal part of CGRP binds to the NH2 terminal of the ex-
tracellular domain of the receptor, during the second 
step the NH2 terminal of the protein binds to the juxta 
membrane region of the receptor, leading to the activa-
tion of intracellular pathways [57]. An additional pro-
tein called receptor component protein (RCP), a small 
membrane-associated protein, is needed for the activa-
tion of the cyclic adenosine monophosphate (cAMP)- 
and inositol diphosphate (IP2)-generating pathways 
(Fig. 3). RCP is not necessary for receptor activation 
but is essential for proper signal transduction [58].  
Mapping of CGRP and its receptors in the trigemi-
novascular system allows the identification of potential 
sites of action of anti-CGRP therapies [59-62]. In 2000, 
Boehringer Ingelheim presented the first selective non-
peptide CGRP antagonist, Olcegepant [63]. In phase II 
clinical trials, the effect of Olcegepant was comparable 
to the effect of triptans, having no influence on sys-
temic hemodynamics, suggesting that Olcegepant will 
not have cardiovascular side effects [64]. Due to its 
 
Fig. (2). Structure of α-CGRP and β-CGRP. CGRP is a 37-amino-acid protein having two active forms: α-CGRP expressed in 
the CNS and β-CGRP expressed in the enteric nervous system. Their structure differs in three amino acids. 
CGRP = calcitonin gene-related peptide. 
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Fig. (3). Binding of CGRP to its receptors. The receptor for CGRP is considered to be formed by the CLR/RAMP1 complex, 
where CLR has seven whereas RAMP1 has one transmembrane domain. For the optimal function of the protein, another mem-
brane-associated component, called RCP, is needed. Binding of CGRP to the receptor leads to the activation of intracellular 
signaling pathways: 1. Elevation of cAMP, leading to activation of PKA, resulting in gene transcription and protein synthesis. 
NO production might occur following phosphorylation of NOS. 2) Another signaling pathway mediated by IP2 results in Ca2+ 
release from the endoplasmic reticulum. 
Abbreviatons: CGRP- Calcitonin gene-related peptide, CLR- calcitonin receptor-like receptor, RAMP1- receptor activity 
modifying protein 1, RCP- receptor component protein. AC- adenylate cyclase, cAMP- cyclic adenosine monophosphate, PKA- 
protein kinase A, NOS- nitric oxide synthase, IP2- inositol-diphosphate, DAG- diacylglycerol, IP3- inositol triphosphate. 
high molecular weight Olcegepant (and being a dipep-
tide) could only be administrated intravenously [65]. A 
great effort has been invested in the development of 
orally available CGRP antagonists. In 2007, Merck 
published details of Telcagepant with oral administra-
tion reported to be potent in acute migraine treatment 
[66, 67]). The studies had to be interrupted at phase III 
clinical trials due to elevated transaminase levels and 
hepatotoxicity following twice daily Telcagepant ad-
ministration for 3 months [68]. Although many com-
pounds of this class have been proven effective in mi-
graine treatment, their clinical development had to be 
suspended due to side-effect associated with long-term 
use [69]. More recently, monoclonal antibodies target-
ing CGRP or its receptors have been developed. Zeller 
et al. have shown for the first time that function-
blocking CGRP antibodies were able to block neuro-
genic vasodilation in the skin and meningeal blood ves-
sels in rats [70]. These monoclonal anti-CGRP antibod-
ies are macromolecules that bind to CGRP and neutral-
ize the excessively released CGRP from the trigeminal 
nerve fibers, or target CGRP receptors, blocking CGRP 
induced activation of the trigeminovascular system. 
These antibodies have various potential benefits com-
pared to CGRP antagonists in the light of their bio-
chemical properties [69]: 1. the target specificity of 
monoclonal antibodies prevents appearance of side-
effects, such as off-target hepatotoxicity, 2. due to their 
pharmacokinetic profile and long-term half-life a less 
frequent dosing is needed [71]. Anti-CGRP antibodies 
are macromolecules, unable to pass the blood-brain 
barrier (BBB), thus the conclusion appears obvious that 
their effect can only be exerted through a peripheral 
site of action delivered through the intravenous or sub-
cutaneous routes [69]. The development of such mono-
clonal antibodies represents a great challenge compared 
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to that of small molecules as their immunogenicity in-
fluences the pharmacokinetic properties and their toxic-
ity. Therefore, different types of bioanalytical assays 
are needed for their early development [72]. Another 
disadvantage might be the result of systemic immu-
nological presenting as an immune response against the 
therapeutic protein. Therefore, most antibodies are hu-
manized mAbs, and anti-drug antibodies need to be 
screened prior treatment to prevent immunological 
side-effects [71]. These anti-drug antibodies are able to 
diminish the effect of mAbs either by uplifting the 
clearance of the antibodies, which leads to their re-
duced concentration, or by preventing the mAbs to 
bind to their target [70]. Three anti-CGRP and one anti-
CGRP receptor mAb are under development. 
LYD2951742 (Arteaus Therapeutics, USA, Eli Lilly 
and Co., USA) has been proven to have better outcome 
than placebo in phase II clinical studies and three phase 
III studies are underway [73, 74]. ALD 403 (Alder 
Biopharmaceuticals, USA) has shown promising re-
sults in a phase II trial [75]. The ongoing phase III trial 
is planned to be completed in June 2017 [74]. 
LBR101/TEV-48125 (Labys Biologics, Pfizer, USA - 
Teva Pharmaceuticals, USA) has been proven to be 
efficient in migraine prevention [76] and an ongoing 
phase III clinical trial will be completed by October 
2017 [74]. AMG 334 (Amgen, USA-Novartis) is the 
only mAb that targets the CGRP receptors [77]. A 
phase III trial was started in 2015 and will end in 
March 2017 [74]. Details of mAbs are summarized in 
Table 1. 
Due to their serious side effects during long-term 
use, the future therapeutic role of CGRP and CGRP 
receptor antagonists is questionable and their clinical 
use is limited. The most promising novel therapeutic 
line is represented by mAbs. Although their oral ad-
ministration is not possible, the infrequent dosing leads 
to better compliance as being more acceptable for the 
patients. The fact that mAbs are large molecules not 
able to penetrate the BBB prevents CNS-related side 
effects, and they do not affect the liver or the kidney. 
Further studies providing detailed assessment of safety 
and tolerability aspects during long-term use are ea-
gerly awaited. 
2.2. Substance P 
SP is an 11-amino-acid protein (Fig. 4), known to 
be another key mediator implicated in neurogenic in-
flammation. Release of SP from trigeminal nerve end-
ings causes plasma protein extravasation and vasodila-
tion [78]. SP binds to three tachykinin receptors (NK1, 
NK2, NK3) with highest affinity to NK1. The NK1 re-
ceptor is a G protein-coupled receptor or a seven-
transmembrane receptor. For SP binding, the N-
terminal segment and the third and seventh transmem-
brane domain has major importance. PRP 100893, a 
non-peptide NK1 receptor antagonist, a member of the 
perhydroindolone family, has been suggested as a 
therapeutic target in migraine, having been reported to 
block neurogenic inflammation in animal models [79]). 
Unfortunately, clinical studies (double blind, placebo 
controlled) were not able to support the positive effects 
of NK1 receptor antagonists either in acute or in the 
prophylactic treatment of migraine. Nevertheless, no 
side-effects have been noted [80, 81]. In the light of 
their ineffectiveness, future studies involving SP have 
not been undertaken. The role of SP remains a question 
of debate for migraine scientists, considering that SP 
Table 1. Monoclonal antibodies targeting CGRP and its receptors. 
Monoclonal Antibody Target Type of Headache Route of  
Administration 
Ongoing Clinical Study 
LYD2951742 CGRP episodic/chronic mi-
graine 
s.c. Phase 3 (June Sep-
tember 2017, April 
2018) 
ALD403 CGRP frequent epi-
sodic/chronic mi-
graine 
i.v. Phase 3 (June 2017) 
LBR101/TEV-48125 CGRP frequent epi-
sodic/chronic mi-
graine 
s.c. Phase 3 (October 
2017) 
AMG 334 CGRP receptor episodic/chronic mi-
graine 
s.c. Phase 3 (March 2017, 
February 2018) 
Migraine, Neurogenic Inflammation, Drug Development Current Medicinal Chemistry, 2017, Vol. 24, No. 00    7 
levels were not elevated during spontaneous migraine 
attacks, in contrast with CGRP [82, 83]. Another ex-
planation might be that dural plasma extravasation does 
not in fact play a crucial role in migraine pathomecha-
nism [84]. To our knowledge, no ongoing studies have 
been reported regarding SP. The questionable role of 
SP in migraine pathophysiology and the ineffectiveness 
of NK-1 receptor antagonists together make any future 
attempt on novel therapeutic approaches regarding SP 
beyond reason.  
2.3. Nitric Oxide 
Nitric oxide (NO) is a labile gas with pleiotropic ef-
fects in different organs and especially in the brain. NO 
is produced by three iso-enzymes, called nitric oxide 
synthases (NOS): neuronal NOS (nNOS), endothelial 
NOS eNOS) and inducible NOS (iNOS) [85]. NOS 
consists of two domains that work independently. The 
first is a C-terminal reductase domain, which represents 
the binding site for NADPH and Ca-calmodulin. Bind-
ing of Ca- calmodulin triggers the activation of NOS 
[86]. The N-terminal region contains a binding site to 
tetrahydrobiopterin (BH4), heme and L-Arginine (L-
Arg) [87]. From the three iso-enzymes, iNOS is the 
only NOS the activity of which is unrelated to the Ca-
calmodulin complex and dependent on its de novo syn-
thesis caused by various inflammatory cytokines (e.g., 
interferon-gamma) [88]. In migraine, NO is supposed 
to be produced in the perivascular nerve endings [89], 
and human studies have shown increase of platelet ni-
trates, known as markers of endogenous NO produc-
tion, suggesting a possible role of NO in migraine 
pathophysiology [90]. A non-selective NOS inhibitor, 
namely N(G)-mono-methyl-L-arginine (L-NMMA), 
lead to pain relief in migraine attack; however, poten-
tial vascular side-effects (bradycardia and high blood 
pressure) due to eNOS inhibition have also been noted 
[91]. Therefore, a scientific demand has been raised 
related to selective iNOS and/or nNOS inhibitors. The 
role of iNOS has been suggested in inflammation; 
therefore, selective iNOS inhibitors have been tested in 
migraine (GW274150, GW273629) [92]. No superior-
ity has been reported compared to placebo in human 
studies either in acute treatment or for prophylaxis 
[93]. A new selective iNOS inhibitor and 5-HT1B/1D 
receptor agonist has shown promising results in pre-
clinical studies [94], but phase II clinical studies have 
failed to show efficacy in acute treatment [95]. With 
regard to NOS inhibitors it needs to be considered that 
NO can be harmful, especially in terms of oxidative 
stress. Nevertheless, it is also needed for physiological 
processes in the brain; therefore, any future therapeutic 
strategies involving modulation of NO synthesis should 
be handled carefully. 
2.4. Vasoactive Intestinal Peptide 
VIP is a 28-amino-acid peptide, a member of the se-
cretin/glucagon superfamily, which acts on G protein-
coupled receptors [96]. Despite its proposed role in 
protein extravasation, current studies have questioned 
its role in migraine pathogenesis. Intravenous infusion 
of VIP indeed caused vasodilation in the temporal su-
perficial artery; however, it did not induce migraine 
attacks [97]. Interestingly though, a recent study has 
reported increased VIP levels in the serum of chronic 
migraine patients compared to healthy subjects [98]. In 
conclusion, we assume that VIP might have a strong 
vasodilator effect, but its role in initiating migraine at-
tack is uncertain. To our knowledge, there are no ongo-
ing clinical studies targeting VIP or its receptors. 
 
Fig. (4). Sequences of substance P, PACAP-27, and PACAP-38. The figure presents the amino acid sequences of substance P, 
built from 11 amino acids, PACAP-27, and PACAP-38 (the two active forms of PACAP), built from 27 and 38 amino acids, 
respectively. PACAP-27 is a polypeptide fragment of PACAP-38 being able to induce the activation of intracellular signaling 
pathways. 
PACAP-27 = 27-amino-acid isoform of pituitary adenylate cyclase-activating polypeptide; PACAP-38 = 38-amino-acid iso-
form of pituitary adenylate cyclase-activating polypeptide. 
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2.5. Pituitary Adenylate Cyclase-activating Peptide 
PACAP is a member of the VIP/secretin/glucagon 
family first isolated in 1989 from ovine hypothalamus 
extract and named after its ability to stimulate cAMP in 
rat pituitary cells [99]. Sequencing of the peptide 
showed that it’s C-terminal is α-amidated and it con-
sists of 38 amino acids (Fig. 4). In the structure of 
PACAP1-38 an internal cleavage-amidation site is 
found, that might cause formation of a polypeptide 
fragment, containing 27 amino acids, called PACAP1-
27 (Figure 4) [99]. PACAP1-27 has proven to be 68% 
identical to VIP with a much higher ability to stimulate 
cAMP (Figure 5) [99-101]. PACAP1-38 and VIP bind 
with the same affinity to VPAC1 and VPAC2 receptors, 
whereas PAC1 receptor has a much higher affinity to 
PACAP1-38 (Fig. 5) [102]. VPAC1 and VPAC2 recep-
tors are G protein-coupled receptors class B having 
seven transmembrane domains. The N-terminal ecto-
domain of the receptor represents the binding site for 
the C-terminal region of VIP and the N-terminal region 
of VIP binds to the first transmembrane domain of the 
receptor, forming a so called ‘Sushi’ domain [103]. 
PACAP1-38 is a pleiotropic molecule shown to be pre-
sent in various components of the trigeminal system 
[89, 104-106] and its role in neurogenic inflammation 
has been suggested by various studies [107, 108]. Ele-
vated levels pf PACAP1-38 were found in the ictal 
phase compared to the interictal phase in migraine pa-
tients [109], and the intravenous administration of 
PACAP1-38 caused delayed migraine-like headache 
[110]. Although PACAP1-38 seems to play a crucial 
role in migraine, some aspects of the nociceptive ef-
fects of PACAP1-38 in migraine pathophysiology are 
still unsettled [111, 112]. PACAP1-38 causes mast cell 
degranulation in the dura mater leading to the activa-
tion of peripheral trigeminal nerve fibers [113, 114]. 
The vasodilatory effect of PACAP1-38 is less potent 
than that of VIP in meningeal and coronary arteries and 
it was not influenced by PAC1-receptor antagonism, 
suggesting that PACAP1-38 does not contribute to mi-
graine pathophysiology via its vasodilatory effect 
[115]. PACAP1-38 induced migraine pain might be 
generated by the activation of the trigeminal nocicep-
tive fibers that innervate the dura via intracellular 
cAMP increase and activation of IP2 pathway initiated 
by the binding of PACAP to PAC1 receptor. While 
PACAP1-38 is supposed to generate migraine via pe-
ripheral mechanisms, the development of such PAC1 
receptor antagonists, that penetrate the blood-brain-
barrier (BBB) might also act centrally on the second-
order neurons and not having vascular side effects 
[116]. In an animal model of dural electrical stimula-
tion, intravenous administration of PAC1 antagonist 
inhibited meningeal vasodilation but did not affect the 
neuronal responses. Only the intra-cerebro-ventricular 
delivery was able to modify activation of the TNC neu-
rons [117]. Maxadilan is a 61 amino acid protein, a po-
tent vasodilator isolated from the saliva of sand flies 
[118]. The maxadilan binding site was found to be the 
PAC1 receptor, making maxadilan a PACAP1-38 re-
ceptor agonist [119]. Deletion of amino-acids between 
position 24 and 42 generated M65, a potent and selec-
tive PAC1 antagonist [120]. No human studies have 
been performed to test PAC1 receptor antagonists as a 
novel therapeutic tool in acute migraine treatment [116, 
121]. Additionally, the presence of a novel, not yet 
identified PACAP1-38 receptor has been suggested, as 
PACAP induced CGRP release from the TNC, but not 
from the TG or the dura mater. Strikingly, this effect 
was not mediated by any of the already known recep-
tors [122] yielding a potential target for new therapeu-
tic strategies. Taken all together, a high amount of evi-
dence suggest that PACAP1-38 and its receptors play a 
pivotal role in the initiation of a migraine attack and the 
sensitization the pain. Regarding future perspectives 
PACAP1-38 might act as a biomarker for migraine at-
tack, and therapies acting on PACAP1-38 and its re-
ceptors might represent new strategies for drug discov-
ery. Current efforts focus on understanding the exact 
role of PACAP1-38 in migraine. 
2.6. Kynurenic Acid 
Tryptophan (TRP), an essential α-amino-acid, is the 
precursor of the neurotransmitter 5-HT. 5-HT is syn-
thesized involving the action of tryptophan hydroxylase 
[123]. Triptans are small agonist molecules acting on 
5-HT1B/1D receptors and have level A recommendation 
according to EFNS [18, 19]. The major route for TRP 
metabolism is the kynurenine pathway (KP), resulting 
in NAD+ and NADP+ as end products. In this metabolic 
pathway, L-kynurenine (KYN) can be metabolized 
through two branches (Fig. 6): one branch providing 
the neuroprotective kynurenic acid (KYNA) and an-
other branch providing the neurotoxic quinolinic acid 
(QUIN) [124-126]. Both neuroactive molecules have 
been shown to play important roles in various CNS 
diseases [127, 128]. N-methyl-D-aspartate (NMDA) 
receptor consists of three subunits (NR1, NR2, and 
NR3) and is activated by Glu and glycine. Glycine is 
essential for NMDA receptor function with the glycine 
binding site being located on the NR1 subunit [129, 
130]. In higher (micromolar/millimolar) doses, KYNA 
acts on the strychnine-insensitive glycine binding site 
of the NMDA receptor [130]. In low (nanomolar) con-
Migraine, Neurogenic Inflammation, Drug Development Current Medicinal Chemistry, 2017, Vol. 24, No. 00    9 
centrations, however, KYNA enhances α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-
sensitive Glu receptors [131, 132]. A key enzyme of 
the KP is the indolamine 2,3-dioxygenase (IDO), 
which was shown to be modulated by the immune sys-
tem via inflammatory cytokines and molecules (Fig. 6) 
[133]. This may explain the low availability of 5-HT in 
the interictal phase of migraine [134].  
In a model of electrical stimulation of the rat TG, 
immunoreactivity of kynurenine aminotransferase 
(KAT), the synthesizing enzyme of KYNA, was re-
ported to be decreased in dural mast cells, macro-
phages, and Schwann cells [135]. A possible site of 
action of KYNA might be the TG [134, 136]. In the 
TNC, KYNA was not able to attenuate nitroglycerin-
induced activation [137], as KYNA can poorly 
penetrate the BBB. In turn, L-kynurenine (L-Kyn) 
combined with probenecid were able to mitigate the 
activation of second-order neurons in the TNC both in 
the model of electrical stimulation of the TG [137], and 
in the nitroglycerin model [138]. In order to facilitate 
BBB penetration, novel KYNA-derivates are being 
synthesized by our research group (Fig. 7) [139]. The 
KYNA amide has been designed in the Department of 
Pharmaceutical Chemistry and Research Group for 
Stereochemistry, University of Szeged Hungary. The 
synthesis was performed by adding 2-
dimethylaminoethylamine followed by treatment with 
ethanolic hydrogen chloride, yielding N-(2-N,N-
dimethylaminoethyl)-4-oxo-1H-quinoline-2-
carboxamide hydrochloride. Structural properties of 
KYNA derivate are: the presence of a water-soluble 
side-chain, the inclusion of a new cationic center, and 
aside-chain substitution (Fig. 7) in order to facilitate 
brain penetration [140].  
Our research group has developed an animal model 
of migraine chronification, using complete Freund’s 
Adjuvant (CFA) on the rat dura mater that causes 
pERK1/2, Il-1β and CGRP activation in the TG [141]. 
This effect was mitigated by a novel KYNA derivate 
[142]. In another experimental model, CFA was in-
jected into the temporomandibular joint of rat, inducing 
inflammation in the TG, which was subsequently miti-
gated by KYNA and KYNA derivate [143]. Beside the
 
Fig. (5). Binding of PACAP to its receptor. PAC1 is a seven-transmembrane protein receptor. Binding of PACAP-38 to PAC1 
causes increase in intracellular cAMP levels, leading to the activation of various signaling pathways described in Fig. 3.  
AC = adenylate cyclase; cAMP = cyclic adenosine monophosphate; DAG = diacylglycerol; IP2 = inositol diphosphate; IP3 = 
inositol triphosphate; NOS = nitric oxide synthase; PACAP = pituitary adenylate cyclase-activating polypeptide; PAC1 = pitui-
tary adenylate cyclase-activating polypeptide receptor 1; PKA = protein kinase A. 
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Fig. (6). Kynurenine pathway and inflammation. The major route for TRP metabolism is the kynurenine pathway (KP). The 
figure presents a simplified version of the KP. In the first metabolic step, TRP is converted to KYN in a process mediated by 
IDO1. KMO mediates the metabolism of KYN into 3HK, converted after multiple metabolic steps to QUIN, a neurotoxic me-
tabolite. The other, neuroprotective branch of the KP is mediated by KAT, resulting in the production of KYNA. Inflammatory 
mediators increase the activity of IDO1 and KMO, leading to elevated levels of 3HK and QUIN. Inflammatory mediators have 
no effect or even decrease the activity of KAT. Excess peripheral 3HK and KYN can be transported across the blood-brain bar-
rier (BBB) and can be used for further QUIN production in the CNS. QUIN cannot pass the BBB. Microglia and macrophages, 
cells that under inflammatory conditions can cross the BBB, express the KMO branch of the KP, leading to elevated levels of 
toxic 3HK and QUIN. On the other hand, astrocytes contain KAT, converting TRP to KYNA, and they are unable to produce 
QUIN, as they lack KMO. 
CNS = central nervous system; 3HK = 3-hydroxykynurenine; IDO1 = indolamine 2,3-dioxygenase 1, KAT = kynurenine 
aminotransferase; KMO = kynurenine 3-monooxygenase; KYN = L-kynurenine; KYNA = kynurenic acid; QUIN = quinolinic 
acid; TRP = tryptophan. 
 
 
Fig. (7). Kynurenic acid (KYNA) and its derivates. 1. Chemical structure of KYNA; 2. General chemical structure of the 
KYNA derivates produced by our research group, aiming to facilitate blood-brain-barrier (BBB) penetration by inclusion of a 
new cationic side-chain; 3, 4. Chemical structure of the two most commonly used KYNA derivates in animal models of tri-
geminovascular activation having the following structural properties: a new cationic center, presence of a water-soluble side-
chain and a side-chain substitution to help crossing through the BBB.  
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peripheral action, a potential central modulatory effect 
of KYNA analogues would be useful in preventing 
central sensitization [134]. The new KYNA analogues 
have proved their efficacy in the TNC following nitro-
glycerin-induced c-fos activation [138, 144]. The spec-
trum of action that occurs following the treatment with 
different KYNA analogues is still untangled. Ongoing 
behavioral, immunohistochemical and pharmacokinetic 
studies might elucidate the possible effect site of the 
KYNA analogues [145]. A possible interaction be-
tween KYNA and inflammatory cytokines (IFNα, 
IFNγ, TNFα, TGF-β, IL-1β, IL4, IL6, IL23) suggests 
an interaction between the kynurenine pathway and the 
immune system, leading to the idea that one possible 
site of action for KYNA derivates could be neurogenic 
inflammation [146, 147]. Summarizing all the above 
mentioned preclinical and clinical studies, we conclude 
that the KP is involved in the pathophysiology of mi-
graine. KYNA analogues might be able to pass the 
BBB might also have a central effect beside that on the 
TG. Future clinical studies are needed to elucidate po-
tential alterations in the KP in migraine. In animal ex-
periments, KYNA analogues represent a promising 
innovative antimigraine therapy.  
CONCLUSION 
Epidemiological studies have demonstrated that mi-
graine is an important socio-economic problem, having 
huge impact on individual health and wellbeing. Large 
neurobiological efforts have revealed partly the patho-
physiology of migraine and the underlying phenomena 
that might generate migraine pain. Animal models aim-
ing at the activation of primary or secondary trigeminal 
neurons have been developed, and various human stud-
ies and genetic investigations have been performed. In 
spite of all the advances in neurobiology of primary 
headache diseases, the role of neurogenic inflammation 
as an initiator of migraine headache pain (heralding for 
decades) remains a subject of debate among scientists. 
Undoubtedly, activation of dural afferents occurs with 
the release of CGRP and SP. This leads to plasma pro-
tein extravasation and release of pro-inflammatory cy-
tokines causing sterile inflammation. Currently, mi-
graine is treated either with general pain-killers 
(NSAID), not specific to migraine pain, or drugs with 
unpredictable effectiveness that might have severe 
side-effects. Triptans represent the gold-standard in the 
current treatment of migraine. However, they are not 
recommended for patients with high cardiovascular risk 
and can also lead to medication overuse headache; 
therefore, they are not recommended for chronic mi-
graine. BoNTA could represent a good therapeutic 
strategy for chronic migraine treatment, but its way of 
administration might influence patient-compliance. 
Further studies are needed to better understand mi-
graine pain and promote the development of new, 
commercially available drugs that offer consistent effi-
cacy and acceptable pain-relief. While a number of 
challenges persist in migraine treatment, its complex 
pathophysiology offers great opportunities for the dis-
covery of new therapeutic strategies. First of all, mi-
graine is a very heterogeneous disease, with many sub-
types and a presumably diverse pathophysiological 
background. The complexity of events potentially oc-
curring during a migraine attack leads to the conclusion 
that variability in treatment response to a certain thera-
peutic target might appear among patients. Another 
problem is the lack of specific biomarkers required for 
drug discovery in any of the primary headache dis-
eases. In spite of the progress that has been achieved in 
migraine research, the diagnosis of primary headaches 
is still based on the clinical symptoms and subjective 
evaluation. 
This review has focused on giving a summary of 
potential therapeutic targets in migraine in relation to 
neurogenic inflammation. The most promising thera-
peutic strategy seems to be related to CGRP and its 
receptor. Despite their efficacy, the first specific CGRP 
antagonists failed due to their hepatotoxic side effects 
but Allergan has restarted the field and ubrogepant, is 
now in phase III for acute therapy in migraine attacks. 
This gepants is likely without liver toxicity. Mono-
clonal antibodies against CGRP and its receptors have 
no such side-effect and have proven demonstrated great 
potency in clinical studies. Ongoing phase III clinical 
studies will presumably end in 2017/2018. Studies in 
relation to SP (NK1 receptor antagonists) and NO 
(NOS antagonist) were terminated due to lack of effi-
cacy, which makes the role of SP and NO questionable 
in migraine attacks. Nevertheless, they might be in-
volved in the pathophysiology of some migraine sub-
types (e.g. NOS antagonists in nitroglycerine induced 
headache); therefore potentially effective in a small 
headache subpopulation with more homogenous clini-
cal features. Preclinical studies have shown effective-
ness of PACAP antagonists and KYNA analogues in 
animal models of dural stimulation. Here we need to 
emphasize the limitations of predictive animal models 
in migraine research, therefore further preclinical stud-
ies are needed in order to understand the role of 
PACAP and KYNA analogues in migraine along with 
clinical studies that assess their effectiveness in acute 
or prophylactic treatment. All these medical leads pro-
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vide hope for novel migraine treatments in the near 
future.  
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